Orthocell (ASX:OCC) cleared for take-off in the US nerve repair market

In a move reminiscent of Cochlear’s first steps into the US audiology market, Perth-based regenerative medicine outfit Orthocell (ASX:OCC) has hit a commercial inflection point, securing coveted US FDA 510(k) clearance for its flagship nerve repair product, Remplir™.

The decision effectively flings open the doors to the US$1.6 billion (A$2.5 billion) American peripheral nerve repair market—a sector that, until now, has been underpenetrated and under-innovated.

“This is a landmark development for the company,” Orthocell CEO Paul Anderson declared. “We have been preparing in advance for this pivotal milestone, ramping up production from our facility in Perth and we have significant levels of inventory in place to deliver on early sales orders.”

For investors and medtech watchers, this isn’t just another regulatory greenlight.

This is a company-defining moment that could pivot Orthocell toward breakeven and profitability, with the bones of a lean and lucrative operating model already in place: no royalties, no debt, and all manufacturing in-house.

Key Highlights:

• FDA 510(k) clearance granted for Remplir™, unlocking US sales.

• Remplir targets a US$1.6 billion addressable market.

• Orthocell is fully funded with ~$32 million in cash to support rollout.

• Manufacturing facility in WA ready to deliver 100,000 units per annum.

• Sales and distribution network in the US already partially established.

Remplir is a collagen-based nerve wrap designed to support the repair and regeneration of damaged nerves—a deceptively simple solution to a complex surgical challenge.

With existing traction in Australia, New Zealand, and Singapore, the leap to the US has been anticipated but not guaranteed.

What sets Orthocell apart? For one, the company isn’t trying to displace an incumbent monolith.

Existing surgical uptake of competing devices hovers around a modest 10%—meaning there’s ample blue ocean for Remplir to carve out territory.

The company’s Perth-based GMP facility, developed in collaboration with UWA’s Professor Minghao Zheng, is more than a manufacturing asset—it’s a strategic moat.

With modular expansion capabilities and no reliance on outsourced production, Orthocell owns every margin.

Anderson added, “We expect strong product adoption in the US, having experienced rapid sales traction in existing markets driven by the excellent feedback from surgeons.”

Unlike many of its ASX-listed biotech peers who often raise funds at every hurdle, Orthocell is heading into the US with a $32 million war chest and no urgent need to tap the market—an all-too-rare posture in Australia’s capital-hungry life sciences sector.

While some might view the FDA nod as a finish line, for Orthocell, it’s the starting gun.

With 12 regional distributors targeted in the next 6 to 12 months and early adopters already engaged, the commercial sprint is just beginning.

Watch this space. Remplir could well be the next home-grown medtech to make surgical waves on a global scale.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.